Skip to main content

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="1" name="CC Event Nav"]

ASH 2018 - Chronic Lymphocytic Leukemia

Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL

ASH 2018 - Chronic Lymphocytic Leukemia

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL

ASH 2018 - Chronic Lymphocytic Leukemia

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

ASH 2018 - Chronic Lymphocytic Leukemia

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL

ASH 2018 - Chronic Lymphocytic Leukemia

MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab

ASH 2018 - Chronic Lymphocytic Leukemia

CLL Treatment Patterns, Dosing, and Sequencing: Interim Analysis Results from the Prospective informCLL Real-World Registry

4
5
6
7
8
9
10

Page 7 of 25
Results 61 - 70 of 242